Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors

Fig. 2

Expression of angiopoietin 1 & 2 in TCM from resected CRC tissue. Human Angiopoietin 1 and Human Angiopoietin 2 Quantikine ELISA kits from R&D systems were used to determine the expression of Angiopoietin 1 and Angiopoietin 2 in tumor conditioned media generated from resected patient CRC tissue. a The expression level of ANGPT1 significantly increased following treatment with FOLFOX (p < 0.05, FC = 2.5, n = 8) and 1,4-dihydroxy quininib in combination with FOLFOX (p < 0.05, FC = 2.5, n = 7) compared to control. b The expression level of ANGPT2 significantly increased following 1,4-dihydroxy quininib treatment (p < 0.05, FC = 2.2, n = 8), and 1,4-dihydroxy quininib treatment in combination with FOLFOX (p < 0.05, FC = 3.9, n = 7) compared to control. Statistical analysis was performed using a paired non-parametric Wilcoxon signed rank test to determine significance between groups. (*p < 0.05). 1,4-dihydrox. Quin. = 1,4-dihydroxy quininib, Bev = Bevacizumab, FC = Fold Change. Error bars represent mean SEM

Back to article page